A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Numerous heart failure trials show new drugs reduce cardiac events and mortality.
• Blinded trial designs can lead to patient clinical decline upon drug withdrawal.
• Delayed access to effective treatments post-trial impacts patient well-being.

Purpose of the Study:

• To propose a framework for ensuring continued patient access to investigational drugs post-trial.
• To advocate for ethical considerations in clinical trial design regarding post-trial access.
• To streamline the process of providing beneficial treatments to patients after trial completion.

Main Methods:

• The study proposes a proactive approach for pharmaceutical sponsors to plan post-trial drug access from the trial's inception.
• It suggests that all participants, regardless of group assignment, should have access to the drug after trial completion, pending safety verification.
• The proposal integrates this access as an ethical requirement for committee approval and trial registration.

Main Results:

• The current system often leaves patients without beneficial treatments for extended periods after trials conclude.
• Withdrawal from effective drugs can rapidly compromise patient clinical status, indicating treatment efficacy.
• Implementing continuous access would mitigate risks associated with treatment interruption.

Conclusions:

• Continued access to effective heart failure drugs post-trial is an ethical imperative.
• Integrating post-trial access into trial design and approval processes is crucial.
• This approach ensures patient benefit and aligns with ethical research standards.